Tumor response after pre-surgery treatment for rectal cancer
Part of Cancer clinical trials.
This study looks at how well the tumor responds to pre-surgery treatment in people with locally advanced rectal cancer. It compares two ways of measuring response to see which better predicts long-term survival, which may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were 18 or older when diagnosed with rectal adenocarcinoma (a type of rectal/colon cancer).
- Your cancer was stage II or III at diagnosis (locally advanced, not spread to distant organs).
- Before surgery, you received total neoadjuvant therapy (TNT): chemoradiation plus chemo, or short-course radiation plus chemo.
- You had surgery (TME) to remove the cancer after your pre-surgery treatment.
- You had no distant metastasis at diagnosis and had complete medical records available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This trial looks at a personalized treatment approach for rectal cancer. It aims to guide the best chemotherapy and (if needed) radiotherapy before and after surgery, based on scans and specific test results.
This study looks at complications that happen after surgery in patients with advanced rectal cancer who got radiation or chemo-radiation before their operation. Researchers want to learn how different pre-surgery treatments affect recovery.
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.